Lidocaine topical gel - Arcion Therapeutics

Drug Profile

Lidocaine topical gel - Arcion Therapeutics

Alternative Names: ARC-2022

Latest Information Update: 15 Sep 2015

Price : $50

At a glance

  • Originator Arcion Therapeutics
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Postherpetic neuralgia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Feb 2010 Phase-I/II clinical trials in Postherpetic neuralgia in Australia (Topical)
  • 10 Jan 2008 Preclinical trials in Pain in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top